Stock listing
Xetra:940 Euroapi SA Aktie
German listing (Xetra) of Euroapi SA · home listing Euronext:EAPI
Follow Euroapi SA into a list and get an email when it puts out news.
Home listing price · EURONEXT:EAPI
€0.642 EUR -0.057 (-8.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:EAPI
- Day range
- €0.629 – €0.680 EURNov 20, 2026
- Volume
- 226,839 sharesNov 20, 2026
- Market cap
- €61.33M EURAt the close on Nov 20, 2026 · price × 95.53M shares outstanding
- 52-week range
- €0.629 – €3.282 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €161,381 EURMedian day 178,041 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:EAPI · Home | €0.642 EUR | -0.057 (-8.2%) | 226,839 | €0.680 | €0.680 | €0.629 | €0.699 | Close on Nov 20, 2026 |
| Frankfurt:940 | €0.645 EUR | -0.037 (-5.4%) | — | €0.645 | €0.645 | €0.645 | €0.682 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:EAPI · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.642 | -0.057 | -8.2% | €0.680 | €0.680 | €0.629 | 226,839 | |
| €0.699 | +0.001 | +0.1% | €0.696 | €0.715 | €0.686 | 182,184 | |
| €0.698 | -0.022 | -3.1% | €0.715 | €0.715 | €0.684 | 236,095 | |
| €0.720 | -0.008 | -1.1% | €0.728 | €0.728 | €0.661 | 641,865 | |
| €0.728 | -0.056 | -7.1% | €0.775 | €0.775 | €0.724 | 227,069 | |
| €0.784 | +0.009 | +1.2% | €0.780 | €0.789 | €0.775 | 94,290 | |
| €0.775 | -0.017 | -2.1% | €0.790 | €0.799 | €0.768 | 105,132 | |
| €0.792 | +0.020 | +2.6% | €0.790 | €0.800 | €0.788 | 164,955 | |
| €0.772 | -0.025 | -3.1% | €0.801 | €0.809 | €0.768 | 317,740 | |
| €0.797 | +0.001 | +0.1% | €0.802 | €0.811 | €0.774 | 261,553 | |
| €0.796 | -0.027 | -3.3% | €0.816 | €0.837 | €0.796 | 170,181 | |
| €0.823 | +0.017 | +2.1% | €0.805 | €0.825 | €0.800 | 111,081 | |
| €0.806 | -0.018 | -2.2% | €0.819 | €0.820 | €0.797 | 71,544 | |
| €0.824 | -0.001 | -0.1% | €0.820 | €0.834 | €0.813 | 126,276 | |
| €0.825 | +0.019 | +2.4% | €0.806 | €0.830 | €0.801 | 177,652 | |
| €0.806 | +0.002 | +0.2% | €0.807 | €0.822 | €0.804 | 113,621 | |
| €0.804 | +0.003 | +0.4% | €0.820 | €0.820 | €0.798 | 101,112 | |
| €0.801 | -0.015 | -1.8% | €0.806 | €0.824 | €0.775 | 244,896 | |
| €0.816 | +0.024 | +3.0% | €0.791 | €0.832 | €0.790 | 265,562 | |
| €0.792 | +0.009 | +1.1% | €0.770 | €0.816 | €0.770 | 369,436 | |
| €0.783 | +0.021 | +2.8% | €0.750 | €0.790 | €0.746 | 211,261 | |
| €0.762 | +0.013 | +1.7% | €0.746 | €0.763 | €0.742 | 61,843 | |
| €0.749 | -0.010 | -1.3% | €0.750 | €0.756 | €0.735 | 115,506 | |
| €0.759 | +0.009 | +1.2% | €0.750 | €0.761 | €0.744 | 103,695 | |
| €0.750 | +0.012 | +1.6% | €0.741 | €0.763 | €0.733 | 180,262 | |
| €0.738 | +0.008 | +1.1% | €0.724 | €0.746 | €0.724 | 51,859 | |
| €0.730 | +0.016 | +2.2% | €0.722 | €0.747 | €0.718 | 199,355 | |
| €0.714 | -0.058 | -7.5% | €0.772 | €0.777 | €0.714 | 428,651 | |
| €0.772 | 0.000 | 0.0% | €0.770 | €0.778 | €0.770 | 34,456 | |
| €0.772 | +0.024 | +3.2% | €0.748 | €0.790 | €0.736 | 208,338 | |
| €0.748 | -0.008 | -1.1% | €0.740 | €0.765 | €0.736 | 197,621 | |
| €0.756 | +0.009 | +1.2% | €0.747 | €0.761 | €0.737 | 144,755 | |
| €0.747 | +0.016 | +2.2% | €0.740 | €0.770 | €0.739 | 303,996 | |
| €0.731 | -0.008 | -1.1% | €0.730 | €0.748 | €0.730 | 116,122 | |
| €0.739 | +0.006 | +0.8% | €0.739 | €0.755 | €0.713 | 247,782 | |
| €0.733 | +0.009 | +1.2% | €0.724 | €0.745 | €0.718 | 378,923 | |
| €0.724 | -0.013 | -1.8% | €0.736 | €0.750 | €0.714 | 168,471 | |
| €0.737 | -0.008 | -1.1% | €0.732 | €0.761 | €0.732 | 178,429 | |
| €0.745 | -0.003 | -0.4% | €0.728 | €0.762 | €0.728 | 229,640 | |
| €0.748 | -0.017 | -2.2% | €0.777 | €0.777 | €0.724 | 365,638 | |
| €0.765 | -0.029 | -3.7% | €0.786 | €0.788 | €0.760 | 174,575 | |
| €0.794 | 0.000 | 0.0% | €0.783 | €0.802 | €0.783 | 176,346 | |
| €0.794 | +0.010 | +1.3% | €0.784 | €0.804 | €0.780 | 250,838 | |
| €0.784 | +0.004 | +0.5% | €0.781 | €0.799 | €0.781 | 129,751 | |
| €0.780 | -0.069 | -8.1% | €0.858 | €0.858 | €0.780 | 302,237 | |
| €0.849 | -0.005 | -0.6% | €0.854 | €0.860 | €0.841 | 85,366 | |
| €0.854 | +0.006 | +0.7% | €0.847 | €0.867 | €0.838 | 149,782 | |
| €0.848 | -0.004 | -0.5% | €0.850 | €0.868 | €0.844 | 183,124 | |
| €0.852 | 0.000 | 0.0% | €0.850 | €0.870 | €0.822 | 201,801 | |
| €0.852 | +0.026 | +3.1% | €0.814 | €0.852 | €0.804 | 147,859 | |
| €0.826 | +0.006 | +0.7% | €0.826 | €0.828 | €0.810 | 126,862 | |
| €0.820 | +0.005 | +0.6% | €0.824 | €0.824 | €0.788 | 448,679 | |
| €0.815 | -0.030 | -3.6% | €0.840 | €0.841 | €0.812 | 176,442 | |
| €0.845 | -0.021 | -2.4% | €0.864 | €0.864 | €0.841 | 246,540 | |
| €0.866 | -0.001 | -0.1% | €0.860 | €0.873 | €0.850 | 161,115 | |
| €0.867 | -0.043 | -4.7% | €0.901 | €0.905 | €0.850 | 267,246 | |
| €0.910 | +0.003 | +0.3% | €0.907 | €0.923 | €0.901 | 140,652 | |
| €0.907 | -0.012 | -1.3% | €0.910 | €0.926 | €0.905 | 320,055 | |
| €0.919 | -0.013 | -1.4% | €0.932 | €0.940 | €0.910 | 507,715 | |
| €0.932 | -0.015 | -1.6% | €0.943 | €0.960 | €0.932 | 81,831 | |
| €0.947 | +0.006 | +0.6% | €0.945 | €0.952 | €0.930 | 98,285 | |
| €0.941 | -0.007 | -0.7% | €0.940 | €0.959 | €0.937 | 143,513 | |
| €0.948 | +0.006 | +0.6% | €0.942 | €0.953 | €0.921 | 259,486 | |
| €0.942 | -0.037 | -3.8% | €0.974 | €0.976 | €0.935 | 236,731 | |
| €0.979 | +0.002 | +0.2% | €0.980 | €0.991 | €0.970 | 91,619 | |
| €0.977 | -0.002 | -0.2% | €0.988 | €0.990 | €0.969 | 108,981 |
- Ticker
- Xetra:940
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Xetra
- Currency
- EUR
What changed lately
Latest news release · Jul 31, 2026
Rapport financier semestriel 2026
Latest deck · Apr 28, 2026
Shareholder Meeting (April 2026)
Shareholder meeting · 15 slides
Latest news
Rapport financier semestriel 2026
Jul 31, 2026
Closed €0.957 (-2.2%) on Aug 3, 2026
Availability of 2026 Half-year results financial report
Jul 31, 2026
Closed €0.957 (-2.2%) on Aug 3, 2026
EUROAPI_Mise à disposition du Rapport Financier Semestriel 2026
Jul 30, 2026
Closed €0.979 (0.0%) on Jul 31, 2026
First-Half 2026 results confirm commercial and operational resilience in a challenging market environment - Transformation progressing as planned, including the divestment of the Brindisi site
Jul 28, 2026
Closed €1.26 (+1.8%) on Jul 29, 2026
Combined General Meeting of May 27, 2026
May 27, 2026
Closed €1.44 (+0.7%) on May 28, 2026
Assemblée Générale Mixte du 27 mai 2026
May 26, 2026
Closed €1.43 (-2.2%) on May 27, 2026
EUROAPI_Liquidity Contract
Apr 30, 2026
Closed €1.37 (+3.9%) on Apr 30, 2026
Availabilty of 2026 AGM preparatory documents
Apr 29, 2026
Closed €1.37 (+3.9%) on Apr 30, 2026
Availability of the 2025 Universal Registration Document, including the Annual Financial Report
Mar 27, 2026
Closed €1.27 (+1.6%) on Mar 30, 2026
2025 results: Core EBITDA margin improved despite sales headwinds, driven by strong cost discipline
Mar 3, 2026
Closed €1.43 (-27.0%) on Mar 4, 2026
Euroapi SA on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 12 in the last 12 months · 22 in all · newest Jul 31, 2026 · oldest 2025
- Decks
- 19 decks · latest Apr 28, 2026
Where Euroapi SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:EAPI · Home listing | Euronext | France | EUR |
| LSIN:0EAP | LSIN | United Kingdom | EUR |
| gettex:940 | gettex | Germany | EUR |
| LS Exchange:A3DJQ8 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3DJQ8 | Lang & Schwarz | Germany | EUR |
| Frankfurt:940 | Frankfurt | Germany | EUR |
| Aquis:EAPIP | Aquis | United Kingdom | EUR |
| OTC:EAPIF | OTC | United States | USD |
| Tradegate:940 | Tradegate | Germany | EUR |
| Aquis:EAPIP | Aquis | United Kingdom | EUR |
| Dusseldorf:940 | Dusseldorf | Germany | EUR |
| Hamburg:940 | Hamburg | Germany | EUR |
| Munich:940 | Munich | Germany | EUR |
| Stuttgart:940 | Stuttgart | Germany | EUR |
| Turquoise:EAPIP | Turquoise | United Kingdom | EUR |
| Hanover:940 | Hanover | Germany | EUR |
| Xetra:940 · This page | Xetra | Germany | EUR |
Valuation
EV/sales 0.4× against a median of 1.1×: the lowest of 11 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €312.6M EUR
- P/E
- Loss
- EV/sales
- 0.4×
- EV/EBITDA
- 31.6×
- Price/book
- 0.1×
- Gross margin
- 17.1%
- Operating margin
- −15.4%
- Net margin
- −24.9%
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Euroapi SA · EURONEXT:EAPI | US$67.31M | US$343.1M | n/a | 0.4× | 31.6× | 0.1× | −24.9% | 0.5× | n/a |
| Domesco Medical Import-Export JSC · HOSE:DMC | US$70.25M | US$47.49M | 9.1× | 0.6× | 5.1× | 1.1× | 9.6% | 0.0× | n/a |
| Zhengye Biotechnology Holding Limited · NASDAQ:ZYBT | US$70.14M | US$73.61M | n/a | 4.2× | n/a | 1.9× | −60.0% | 0.3× | 0.92 |
| OPTUS Pharmaceutical Co. Ltd. · KRX:131030 | US$68.82M | US$37.32M | 6.7× | 0.5× | 3.3× | 0.5× | 14.5% | 0.0× | n/a |
| Vetnostrum Animal Health Co., Ltd. · TWSE:6936 | US$68.48M | US$54.55M | 17.5× | 1.3× | 7.8× | 1.7× | 9.1% | 0.0× | n/a |
| TSH Biopharm Corp. Ltd. · TPEX:8432 | US$68.27M | US$35.76M | 16.2× | 0.9× | 4.8× | 1.6× | 10.4% | 0.0× | n/a |
| Wanbury Limited · NSE:WANBURY | US$67.68M | US$67.68M | 11.2× | 1.0× | 6.4× | 4.3× | 8.6% | 0.0× | n/a |
| Bangkok Lab and Cosmetic Public Company Limited · SET:BLC | US$66.78M | US$65.27M | 16.6× | 1.4× | 9.0× | 1.4× | 8.4% | 0.0× | n/a |
| JW Shinyak Corp. · KRX:067290 | US$66.62M | US$63.79M | 8.7× | 1.0× | 6.9× | 2.2× | 12.1% | 0.0× | n/a |
| Laboratorios Richmond SACIF Class B · BCBA:RICH | US$65.34M | US$173.1M | 8.4× | 2.1× | 7.5× | 0.9× | 9.3% | 1.5× | n/a |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A · TWSE:1762 | US$63.36M | US$76.28M | n/a | 2.7× | 51.1× | 0.7× | −5.5% | 0.2× | n/a |
| Median of the others | US$67.98M | US$64.53M | 10.2× | 1.1× | 6.9× | 1.5× | 9.2% | 0.0× | 0.92 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.95 · 2 analysts
- Revenue, year to Dec 2026
- 748.3M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sophie Palliez-Capian | Investor Relations |
| Cécile Dussart | |
| Elizabeth Bastoni | |
| Emmanuel Blin | |
| Géraldine Leveau | |
| Jean-Yves Caminade | |
| Kevin Rodier | |
| Marie-Isabelle Penet | |
| Mattias Perjos | |
| Olivier Klaric | |
| Tristan Imbert |
Board
| Director |
|---|
| Cécile Dussart |
| Elizabeth Bastoni |
| Emmanuel Blin |
| Géraldine Leveau |
| Jean-Yves Caminade |
| Kevin Rodier |
| Marie-Isabelle Penet |
| Mattias Perjos |
| Olivier Klaric |
| Tristan Imbert |
Events
- Next results
- Mar 3, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Jul 29, 2025 · After close | −7.9% |
| Q4 2024 | Mar 31, 2025 | −3.0% |
| Q1 2023 | Apr 14, 2023 | +1.9% |
| Q2 2022 | Sep 1, 2022 · Before open | +3.6% |
| Q1 2022 | May 3, 2022 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (April 2026) | Shareholder meeting | 15 slides | Apr 28, 2026 |
| FY2025 Earnings Presentation | Earnings | 33 slides | Mar 4, 2026 |
| Investor Presentation (September 2025) | Investor deck | 70 slides | Sep 9, 2025 |
| H1 2025 Earnings Presentation | Earnings | 21 slides | Jul 30, 2025 |
| Shareholder Meeting (May 2025) | Shareholder meeting | 60 slides | May 21, 2025 |
| FY2024 Earnings Presentation | Earnings | 34 slides | Mar 4, 2025 |
| Investor Presentation (October 2024) | Investor deck | 93 slides | Oct 11, 2024 |
| H1 2024 Earnings Presentation | Earnings | 26 slides | Jul 31, 2024 |
| Shareholder Meeting (May 2024) | Shareholder meeting | 48 slides | May 22, 2024 |
| Investor Presentation (May 2024) | Investor deck | 95 slides | May 2024 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2023 Earnings Presentation | Earnings | 53 slides | Feb 29, 2024 |
| Investor Presentation (2024) | Investor deck | 93 slides | 2024 |
| Investor Presentation (November 2023) | Investor deck | 95 slides | November 2023 |
| H1 2023 Earnings Presentation | Earnings | 32 slides | Aug 1, 2023 |
| Shareholder Meeting (May 2023) | Shareholder meeting | 50 slides | May 11, 2023 |
| FY2022 Earnings Presentation | Earnings | 30 slides | Mar 8, 2023 |
| Investor Presentation (2023) | Investor deck | 98 slides | 2023 |
| H1 2022 Earnings Presentation | Earnings | 29 slides | Sep 1, 2022 |
| Investor Day (April 2022) | Investor day | 102 slides | Apr 1, 2022 |
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 848.2M | 919.2M | 1.02B | 980.9M | 892.8M | 944.6M | 915.8M |
| Cost of revenue | 707.7M | 776.8M | 854.3M | 804.0M | 783.7M | 854.1M | 828.2M |
| Gross profit | 144.8M | 142.4M | 164.6M | 176.9M | 109.1M | 90.5M | 87.6M |
| Research and development | 27.3M | 25.8M | 29.6M | 21.8M | 17.0M | 19.9M | 16.3M |
| Selling, general and administrative | 80.3M | 89.4M | 90.0M | 90.5M | 55.4M | 42.7M | 39.3M |
| Operating income | -130.6M | -120.4M | -234.3M | -800.0K | 2.70M | -10.8M | -1.80M |
| Depreciation and amortization | 140.5M | 76.8M | 302.9M | 94.5M | 76.0M | 72.2M | 58.6M |
| EBITDA | 9.90M | -43.6M | 68.6M | 93.7M | 78.7M | 61.4M | 56.8M |
| Interest expense | 11.7M | 28.1M | 10.9M | 4.20M | 2.10M | 1.20M | 1.10M |
| Income before tax | -138.2M | -139.6M | -242.8M | 3.10M | -14.6M | -11.8M | -3.10M |
| Income tax | 72.9M | -9.00M | -53.0M | 18.2M | -6.50M | -5.50M | -5.60M |
| Net income | -211.2M | -130.6M | -189.7M | -15.0M | -8.10M | -6.30M | 2.50M |
| Earnings per share, basic | -2.23 | -1.38 | -2.02 | -0.16 | -0.09 | -0.07 | 0.03 |
| Earnings per share, diluted | -2.23 | -1.38 | -2.02 | -0.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 113.8M | 73.0M | 34.5M | 74.5M | 10.3M | 100.0K | -20.0M |
| Short-term investments | 5.70M | 6.20M | 8.40M | 4.80M | 19.0M | 153.8M | 133.0M |
| Receivables | 114.9M | 161.3M | 216.3M | 264.2M | 256.2M | 213.3M | 220.4M |
| Inventory | 495.2M | 524.2M | 644.8M | 594.7M | 569.5M | 584.1M | 596.9M |
| Current assets | 768.4M | 830.3M | 979.3M | 1.02B | 905.0M | 983.6M | 974.0M |
| Property, plant and equipment | 450.9M | 491.3M | 468.9M | 597.1M | 631.7M | 585.8M | 573.1M |
| Goodwill | 0 | 0 | 4.60M | 0 | |||
| Total assets | 1.30B | 1.49B | 1.61B | 1.74B | 1.62B | 1.60B | 1.58B |
| Accounts payable | 110.5M | 104.9M | 159.6M | 219.6M | 189.6M | 131.1M | 120.4M |
| Current liabilities | 295.1M | 311.2M | 508.9M | 456.5M | 387.7M | 365.3M | 312.5M |
| Total debt | 45.5M | 50.6M | 205.4M | 100.1M | 24.1M | 73.4M | 64.2M |
| Total liabilities | 516.7M | 506.0M | 684.7M | 625.9M | 607.0M | 611.6M | 558.6M |
| Shareholders' equity | 788.0M | 983.5M | 927.7M | 1.11B | 1.01B | 989.4M | 1.02B |
| Shares outstanding | 94.7M | 94.5M | 94.2M | 94.5M | 94.0M | 94.0M | 94.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 128.5M | 122.9M | 5.10M | 44.8M | 71.5M | 96.8M | 34.9M |
| Capital spending | -78.5M | -108.0M | -132.8M | -167.4M | -88.6M | -88.4M | -81.8M |
| Free cash flow | 47.0M | 14.9M | -127.7M | -122.6M | -17.1M | 8.40M | -46.9M |
| Cash from investing | -77.0M | -108.0M | -137.3M | -167.4M | -87.9M | -88.3M | -81.2M |
| Cash from financing | -13.3M | 26.5M | 92.2M | 187.8M | 26.5M | -8.40M | 46.2M |
| Dividends paid | 0 | 0 | 0 | 0 | -4.70M | -6.20M | |
| Share buybacks | 0 | -100.0K | -600.0K | -1.30M | 0 | 100.0K | -52.4M |
| Change in cash | 38.6M | 40.8M | -40.0M | 64.2M | 10.2M | 100.0K | -100.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EUROAPI_Mise à disposition du Rapport Financier Semestriel 2026 | Jul 30, 2026 | Other filings | Euronext |
| First-Half 2026 results confirm commercial and operational resilience in a challenging market environment - Transformation progressing as planned, including the divestment of the Brindisi site | Jul 28, 2026 | Acquisition or disposal | Euronext |
| Assemblée Générale Mixte du 27 mai 2026 | May 26, 2026 | Other filings | Euronext |
Cap table
Built by 6ix from Euroapi SA’s releases
- Common shares
- 95,528,648
- Fully diluted
- 95,528,648
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 95,528,648 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 95,528,648 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cécile Dussart | Director · Since at least Nov 5, 2026 |
| Elizabeth Bastoni | Director · Since at least Nov 5, 2026 |
| Emmanuel Blin | Director · Since at least May 27, 2026 |
| Géraldine Leveau | Director · Since at least Nov 5, 2026 |
| Jean-Yves Caminade | Director · Since at least Nov 5, 2026 |
| Kevin Rodier | Director · Since at least Nov 5, 2026 |
| Marie-Isabelle Penet | Director · Since at least Nov 5, 2026 |
| Mattias Perjos | Director · Since at least Nov 5, 2026 |
| Olivier Klaric | Director · Since at least Nov 5, 2026 |
| Sophie Palliez-Capian | Investor Relations · Since at least Jul 31, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Tristan Imbert | Director · Since at least Dec 10, 2025 |
Log in to ask 6ix AI your own questions about Euroapi SA.